Background/Aim: Acute renal failure (ARF) is one of the common problems associated with sepsis or multiple organ dysfunction syndrome (MODS). We have investigated the effects of inhibiting selectin-mediated cell adhesion on lipopolysaccharide-induced ARF in rabbits, using sialyl Lewis X oligosaccharide and PB1.3, an anti-human P-selectin monoclonal antibody, as inhibitors. Methods: ARF was induced by intravenous administration of lipopolysaccharide (0.3 mg/kg, i.v. bolus injection) to New Zealand White rabbits. Induction of ARF was characterized by increases in blood urea nitrogen (BUN), creatinine, and the number of polymorphonuclear leukocytes infiltrating glomeruli, and by fibrin deposition in glomeruli, and tubular dilatation in the kidney. Sialyl Lewis X oligosaccharide (14 mg/kg, i.v. bolus injection immediately before lipopolysaccharide administration and 9 mg/kg/h, i.v. infusion) or PB1.3 (5 mg/kg, i.v. bolus injection before lipopolysaccharide administration), anti-P-selectin antibody, were treated. Results: Treatment with sialyl Lewis X oligosaccharide inhibited the increases in BUN, creatinine, and the number of infiltrating polymorphonuclear leukocytes, and attenuated histopathological impairments. Similarly, treatment with PB1.3 prevented some of the characteristics associated with lipopolysaccharide-induced ARF, not but the increase in creatinine. Conclusion: These results suggest that selectin inhibitors, including sialyl Lewis X oligosaccharide and PB1.3, may provide clinical benefits in the prevention of ARF associated with sepsis and MODS. To our knowledge, this is the first report that P-selectin is directly involved in lipopolysaccharide-induced ARF in rabbits.

Keywords:
Acute renal failure, Sialyl Lewis X oligosaccharide, P-selectin, Lipopolysaccharide
1.
Lote CJ, Harper L, Savage COS: Mechanisms of acute renal failure. Br J Anaesth 1996;77:82–89.
2.
Thiemermann C, Ruetten H, Wu CC, Vane JR: The multiple organ dysfunction syndrome caused by endotoxin in the rat: Attention of liver dysfunction by inhibitors of nitric oxide synthase. Br J Pharmacol 1995;116:2845–2851.
3.
Zurovsky Y, Gispaan I: Antioxidants attenuate endotoxin-induced acute renal failure in rat. Am J Kidney Dis 1995;25:51–57.
4.
Jochimsen F, Schäfer JH, Maurer A, Distler A: Impairment of renal function in medical intensive care: Predictability of acute renal failure. Crit Care Med 1990;18:480–485.
5.
Groeneveld ABJ, Tran DD, Meulen JVD, Nauta JJP, Thijs LG: Acute renal failure in the medical intensive care unit: Predisposing, complicating factors and outcome. Nephron 1991;59:602–610.
6.
Turney JH: Why is mortality persistently high in acute renal failure? Lancet 1990;335:971.
7.
Mulligan M, Johnson KJ, Todd VRF III, Issekutz TB, Miyasaka M, Tamatani T, Smith CW, Anderson DC, Ward PA: Requirements for leukocyte adhesion molecules in nephrotoxic nephritis. J Clin Invest 1993;91:577–587.
8.
Schramm L, Heidbreder E, Lukes M, Weierich T, Lopau K, Zimmermann J, Wanner C: Endotoxin-induced acute renal failure in the rat: Effect of urodilatin and diltiazem on renal function. Clin Nephrol 1996;46:117–124.
9.
Heneka MT, Löschmann P, Osswald H: Polymerized hemoglobin restores cardiovascular and kidney function in endotoxin-induced shock in the rat. J Clin Invest 1997;99:47–54.
10.
Granger DN, Kubes P: The microcirculation and inflammation: Modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 1994;55:662–675.
11.
Briscoe DM, Cotran DS: Role of leukocyte-endothelial cell adhesion molecules in renal inflammation: In vitro and in vivo studies. Kidney Int 1993;44(suppl 42):27–34.
12.
Tedder TF, Steeber DA, Chen A, Engel P: The selectins: Vascular adhesion molecules. FASEB J 1995;9:866–873.
13.
Kansas GS: Selectins and their ligands: Current concepts and controversies. Blood 1996;88:3259–3287.
14.
Foxall C, Watson SR, Dowbenko D, Fennie C, Lasky LA, Kiso M, Hasegawa A, Asa D, Brandley BK: The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis X oligosaccharide. J Cell Biol 1992;117:895–902.
15.
Phillips ML, Nudelman E, Gaeta FCO, Perez M, Singhal AK, Hakomori S, Paulson JC: ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-LeX. Science 1990;250:1130–1132.
16.
Lefer DJ, Flyn DM, Phillips ML, Ratcliffe M, Buda AJ: A novel sialyl LewisX analog attenuates neutrophil accumulation and myocardial necrosis after ischemia and reperfusion. Circulation 1994;90:2390–2401.
17.
Tojo SJ, Yokota S, Koike H, Schultz J, Hamazume Y, Misugi E, Yamada K, Hayashi M, Paulson JC, Morroka S: Reduction of rat myocardial ischemia and reperfusion injury by sialyl Lewis X oligosaccharide and anti-rat P-selectin antibodies. Glycobiology 1996;6:463–469.
18.
Yamada K, Tojo SJ, Hayashi M, Morooka S: The role of P-selectin, sialyl Lewis X and sulfatide in myocardial ischemia and reperfusion injury. Eur J Pharmacol 1998;346:217–225.
19.
Han KT, Sharar SR, Phillips ML, Winn RK: Sialyl Lewis X oligosaccharide reduces ischemia-reperfusion injury in the rabbit ear. J Immunol 1995;155:4011–4015.
20.
Mulligan MS, Lowe JB, Larsen RD, Paulson JC, Zheng ZL, Defrees S, Maemura K, Fukuda M, Ward PA: Protective effects of sialylated oligosaccharides in immune complex-induced acute lung injury. J Exp Med 1993;178:623–631.
21.
Winn RK, Liggitt D, Vedder NB, Paulson JC, Harlan JM: Anti-P-selectin monoclonal antibody attenuates reperfusion injury to the rabbit ear. J Clin Invest 1993;92:2042–2047.
22.
Hayashi H, Koike H, Kurata Y, Imanishi N, Tojo SJ: Protective effects of sialyl Lewis X and anti-P-selectin antibody against lipopolysaccharide-induced acute lung injury in rabbits. Eur J Pharmacol 1999;370:47–56.
23.
Ohnishi M, Imanishi N, Tojo SJ: Protective effect of anti-P-selectin monoclonal antibody in lipopolysaccharide-induced lung hemorrhage. Inflammation 1999;23:461–469.
24.
Tipping PG, Huang XR, Berndt MC, Holdsworth SR: A role of P-selectin in complement-independent neutrophil-mediated glomerular injury. Kidney Int 1994;46:79–88.
25.
Zachen CR, Alpers CE, Way W, Shankland SJ, Couser WG, Johnson RJ: A role of P-selectin in neutrophil and platelet infiltration in immune complex glomerulonephritis. J Am Soc Nephrol 1997;8:1838–1844.
26.
Redl H, Dinges HP, Buurman WA, Van der Linden CJ, Pober JS, Cotran RS, Schlag G: Expression of endothelial leukocyte adhesion molecule-1 in septic but not traumatic/hypovolemic shock in the baboon. Am J Pathol 1991;139:461–466.
27.
Johnson RJ, Alpers CE, Pruchno C, Schulze M, Baker PJ, Pritzl P, Couser WG: Mechanisms and kinetics for platelet and neutrophil localization in immune complex nephritis. Kidney Int 1989;36:780–789.
28.
Schrijver G, Bogman MJJT, Assmann KJM, De Waal RMW, Robben HCM, Gasteren HV, Koene RAP: Anti-GBM nephritis in the mouse: Role of granulocytes in the heterologous phase. Kidney Int 1990;38:86–95.
29.
Brady HR: Leukocyte adhesion molecules and kidney diseases. Kidney Int 1994;45:1285–1300.
30.
Ridings PC, Holloway S, Bloomfield GL, Phillips ML, Fisher BJ, Blocher CR, Sugerman HJ, Fowler AA III: Protective role of synthetic sialylated oligosaccharide in sepsis-induced acute lung injury. J Appl Physiol 1997;82:644–651.
31.
Honkanen E, Von Willebrand E, Teppo AM, Tornroth T, Gronhagen-Riska C: Adhesion molecules and urinary tumor necrosis factor-α in idiopathic membranous glomerulonephritis. Kidney Int 1998;53:909–917.
32.
Brockmeyer C, Ulbrecht M, Schendel DJ, Weiss EH, Hillebrand G, Burkhardt K, Land W, Gokel MJ, Riethmuller G, Feucht HE: Distribution of cell adhesion molecules (ICAM-1, VCAM-1, ELAM-1) in renal tissue during allograft rejection. Transplantation 1993;55:610–615.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.